Search Results
10
Everything
Search Filters
Organization
Lisata Therapeutics
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
February 20, 2025 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
February 05, 2025 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
January 23, 2025 08:00 ET
|
Lisata Therapeutics, Inc.
Data corroborate previously reported preclinical data demonstrating certepetide’s ability to enhance the effectiveness of immunotherapy Preliminary results to be presented at the 2025 ASCO...
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
January 22, 2025 08:00 ET
|
Lisata Therapeutics, Inc.
Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall survival, including 4...
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
January 15, 2025 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment...
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
December 10, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment...
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
December 03, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J. and HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
November 19, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
Award recognizes Lisata’s data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors Annual BioTech Breakthrough Award is devoted...
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
Lisata Therapeutics, Inc.
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. ...
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
November 06, 2024 09:23 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the...